284 related articles for article (PubMed ID: 35151825)
21. The prognostic effect of PNN in digestive tract cancers and its correlation with the tumor immune landscape in colon adenocarcinoma.
Zhang H; Jin M; Ye M; Bei Y; Yang S; Liu K
J Clin Lab Anal; 2022 Apr; 36(4):e24327. PubMed ID: 35257416
[TBL] [Abstract][Full Text] [Related]
22. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
23. Alteration in the Immune Microenvironment Based on APC Status in MSS/pMMR Colon Cancer.
Lin H; Cao B
Dis Markers; 2022; 2022():3592990. PubMed ID: 35937946
[TBL] [Abstract][Full Text] [Related]
24. A Prognostic Model Based on the Immune-related Genes in Colon Adenocarcinoma.
Sun YL; Zhang Y; Guo YC; Yang ZH; Xu YC
Int J Med Sci; 2020; 17(13):1879-1896. PubMed ID: 32788867
[No Abstract] [Full Text] [Related]
25. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of m6A regulators and relationship with tumor microenvironment, immunotherapy strategies in colorectal adenocarcinoma.
Ji J; Liu S; Liang Y; Zheng G
BMC Genom Data; 2023 Aug; 24(1):44. PubMed ID: 37568073
[TBL] [Abstract][Full Text] [Related]
27. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.
Wu Z; Zhang X; Chen D; Li Z; Wu X; Wang J; Deng Y
Front Immunol; 2021; 12():806189. PubMed ID: 35095893
[TBL] [Abstract][Full Text] [Related]
28. Identification of prognostic m6A modification patterns and score system in melanoma patients.
Wang F; Chen P; Ouyang S; Xiong K; Liu Z; Wang Y
Medicine (Baltimore); 2024 Apr; 103(17):e37950. PubMed ID: 38669381
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
Lin A; Gu T; Hu X; Zhang J; Luo P
J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
[TBL] [Abstract][Full Text] [Related]
30. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
31. A pairwise immune gene model for predicting overall survival and stratifying subtypes of colon adenocarcinoma.
Jiang Z; Xu J; Zhang S; Lan H; Bao Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10813-10829. PubMed ID: 37316691
[TBL] [Abstract][Full Text] [Related]
32. Integrated analyses of m
Gao Y; Wang H; Li H; Ye X; Xia Y; Yuan S; Lu J; Xie X; Wang L; Zhang J
Oncoimmunology; 2021 Jun; 10(1):1936758. PubMed ID: 34221700
[TBL] [Abstract][Full Text] [Related]
33. The Non-N
Xu J; Gao Z; Liu K; Fan Y; Zhang Z; Xue H; Guo X; Zhang P; Deng L; Wang S; Wang H; Wang Q; Zhao R; Li G
Front Immunol; 2021; 12():809808. PubMed ID: 35154083
[TBL] [Abstract][Full Text] [Related]
34. Gene expression and methylation profiles identified CXCL3 and CXCL8 as key genes for diagnosis and prognosis of colon adenocarcinoma.
Zhao QQ; Jiang C; Gao Q; Zhang YY; Wang G; Chen XP; Wu SB; Tang J
J Cell Physiol; 2020 May; 235(5):4902-4912. PubMed ID: 31709538
[TBL] [Abstract][Full Text] [Related]
35. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
Meijing Z; Tianhang L; Biao Y
Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
[No Abstract] [Full Text] [Related]
36. PLOD3 Is Associated with Immune Cell Infiltration and Genomic Instability in Colon Adenocarcinoma.
Deng X; Pan Y; Yang M; Liu Y; Li J
Biomed Res Int; 2021; 2021():4714526. PubMed ID: 34239923
[TBL] [Abstract][Full Text] [Related]
37. m
Zheng J; Feng P; Chen D; Zhang C; Ji Y; Liu Y; Fan X; Li J
Oxid Med Cell Longev; 2022; 2022():9451480. PubMed ID: 36046691
[TBL] [Abstract][Full Text] [Related]
38. Autophagy-related IFNG is a prognostic and immunochemotherapeutic biomarker of COAD patients.
Yue T; Cai Y; Zhu J; Liu Y; Chen S; Wang P; Rong L
Front Immunol; 2023; 14():1064704. PubMed ID: 36756126
[TBL] [Abstract][Full Text] [Related]
39. Construction of a novel cancer-associated fibroblast-related signature to predict clinical outcome and immune response in colon adenocarcinoma.
Zheng L; Zhang J; Ye Y; Shi Z; Huang Y; Zhang M; Gui Z; Li P; Qin H; Sun W; Zhang M
Aging (Albany NY); 2023 Sep; 15(18):9521-9543. PubMed ID: 37724904
[TBL] [Abstract][Full Text] [Related]
40. Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis.
Wu T; Zhang X; Xing L; Pan D; Liu P; Ding R; Yang R; Yang X; Li Y
Dis Markers; 2022; 2022():5883101. PubMed ID: 35677634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
